Roth Capital lowers Capricor Therapeutics target price to $12

Summary

Roth Capital has lowered its target stock price for Capricor Therapeutics (NASDAQ: CAPR) from $31.00 to $12.00, while maintaining a ‘Buy’ rating. This suggests a potential upside of 62.69% from the current price of $7.38. Other analysts have also adjusted their ratings, with a general target price of $22.56. Capricor’s stock has experienced significant volatility, with a 12-month low of $3.52 and a high of $23.40. The company reported a loss of $0.53 per share last quarter, missing expectations.Market Beat

Impact Analysis

This is a company-level event, as it pertains specifically to Capricor Therapeutics and reflects Roth Capital’s revised outlook on its stock performance. The event indicates a reassessment of the company’s valuation, likely driven by recent financial results where Capricor reported a loss that missed expectations. Such news can have first-order effects, including immediate impacts on Capricor’s stock price as investor sentiment adjusts to the new target. A significant reduction in the target price could lead to selling pressure, although the maintained ‘Buy’ rating and potential for a 62.69% increase from the current price highlight perceived long-term value despite recent setbacks. The second-order effects might involve broader market perceptions of the biotech sector’s volatility, influencing investment strategies towards either risk mitigation or opportunistic buying. The investment opportunity lies in evaluating Capricor’s strategic responses and potential for recovery, considering the risks of continued financial underperformance against the potential upside.Market Beat